117 related articles for article (PubMed ID: 2541044)
1. Potentiating effect of 3-isobutyryl-2-isopropylpyrazolo-[1,5a]-pyridine (KC-404), a new cerebral vasodilator with anti-platelet activity, on prostacyclin-induced increase of cyclic AMP content in platelets of rat.
Hisayama T; Takayanagi I; Goromaru N; Okamoto Y
Gen Pharmacol; 1989; 20(2):183-6. PubMed ID: 2541044
[TBL] [Abstract][Full Text] [Related]
2. A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation.
Ohashi M; Ohkubo H; Kito J; Nishino K
Arch Int Pharmacodyn Ther; 1986 Oct; 283(2):321-34. PubMed ID: 3024600
[TBL] [Abstract][Full Text] [Related]
3. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets.
Nogimori K; Kajikawa N; Nishio S; Yajima M
Prostaglandins; 1989 Feb; 37(2):205-12. PubMed ID: 2543034
[TBL] [Abstract][Full Text] [Related]
4. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators.
Grünberg B; Kruse HJ; Negrescu EV; Siess W
J Cardiovasc Pharmacol; 1995 Apr; 25(4):545-51. PubMed ID: 7596121
[TBL] [Abstract][Full Text] [Related]
5. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.
Weithmann KU
Gen Pharmacol; 1983; 14(1):161-2. PubMed ID: 6298055
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets.
Jakubowski JA; Utterback BG; Mais DE; Hardinger SA; Braish TF; Nevill CR; Fuchs PL
Prostaglandins; 1994 Mar; 47(3):189-201. PubMed ID: 8016389
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin.
Rand ML; Gross PL; Jakowec DM; Packham MA; Mustard JF
Thromb Haemost; 1989 Apr; 61(2):254-8. PubMed ID: 2546284
[TBL] [Abstract][Full Text] [Related]
8. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
Beretz A; Stierle A; Anton R; Cazenave JP
Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
[TBL] [Abstract][Full Text] [Related]
9. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
[TBL] [Abstract][Full Text] [Related]
10. Azelastine potentiates the prostaglandin-induced increase of cyclic AMP content in human platelets and in guinea-pig alveolar macrophages.
Hatmi M; Havet N; Vargaftig BB; Bachelet M
Prostaglandins; 1992 May; 43(5):457-72. PubMed ID: 1374922
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
[TBL] [Abstract][Full Text] [Related]
12. Ibudilast modulates platelet-endothelium interaction mainly through cyclic GMP-dependent mechanism.
Kishi Y; Ohta S; Kasuya N; Tatsumi M; Sawada M; Sakita S; Ashikaga T; Numano F
J Cardiovasc Pharmacol; 2000 Jul; 36(1):65-70. PubMed ID: 10892662
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.
Callahan KS; Johnson AR; Campbell WB
Circulation; 1985 Jun; 71(6):1237-46. PubMed ID: 2986877
[TBL] [Abstract][Full Text] [Related]
14. Studies on antiplatelet effects of OP-41483, a prostaglandin I2 analog, in experimental animals. II. Mechanism of its antiplatelet effect.
Fujitani B; Wakitani K
Jpn J Pharmacol; 1990 May; 53(1):25-33. PubMed ID: 2161965
[TBL] [Abstract][Full Text] [Related]
15. Drug stimulated prostacyclin release.
Weithmann KU
Ric Clin Lab; 1981; 11 Suppl 1():209-14. PubMed ID: 6324324
[TBL] [Abstract][Full Text] [Related]
16. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
Jaschonek K; Faul C; Daiss W; Weisenberger H
Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
[TBL] [Abstract][Full Text] [Related]
17. Intracellular levels of cyclic AMP and cyclic GMP differentially modify platelet aggregate size in human platelets activated with epinephrine or ADP.
Qi R; Ozaki Y; Satoh K; Yang LB; Asazuma N; Yatomi Y; Kume S
J Cardiovasc Pharmacol; 1996 Aug; 28(2):215-22. PubMed ID: 8856476
[TBL] [Abstract][Full Text] [Related]
18. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
Vanderwel M; Haslam RJ
J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
[TBL] [Abstract][Full Text] [Related]
19. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species.
Nishio S; Matsuura H; Kanai N; Fukatsu Y; Hirano T; Nishikawa N; Kameoka K; Umetsu T
Jpn J Pharmacol; 1988 May; 47(1):1-10. PubMed ID: 2842529
[TBL] [Abstract][Full Text] [Related]
20. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
